Key Insights

Highlights

Success Rate

50% trial completion

Treatment Research

12 treatments under study, led by Methotrexate

Related Conditions

Often studied with 20 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 75/100

Termination Rate

33.3%

1 terminated out of 3 trials

Success Rate

50.0%

-36.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results50% success

Data Visualizations

Phase Distribution

3Total
Not Applicable (2)
Phase 2 (1)

Trial Status

Completed1
Unknown1
Terminated1

Trial Success Rate

50.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT01821781Phase 2Completed

Immune Disorder HSCT Protocol

NCT00006054Not ApplicableTerminated

Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies

NCT00006056Not ApplicableUnknown

Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders

Showing all 3 trials

Research Network

Common Treatments

  • Methotrexate2
  • Antithymocyte Globulin2
  • Busulfan2
  • Cyclophosphamide2
  • Cyclosporine2

Active Sponsors

  • Fairview University Medical Center2
  • Washington University School of Medicine1

Top Investigators

Related Conditions

  • Hemophagocytic Lymphohistiocytosis3
  • Chediakhigashi Syndrome3
  • Virusassociated Hemophagocytic Syndrome2
  • Wiskottaldrich Syndrome2
  • Familial Erythrophagocytic Lymphohistiocytosis2

Activity Timeline